To answer this question we have to first discuss the benefits of adjuvant chemotherapy. The almost exclusive focus has been on doxorubicin based therapy, either as a single agent, in combination with ifosfamide, or in 1 case combined with ifosfamide and dtic. Each study individually has small number...

These are not impressive results for a retrospective study where I am sure fitter patients are probably selected for therapy. these are very toxic drugs. Can you break down the numbers of pleomorphic in this abstract ( unpublished) to see if we can get a better idea What level of evidence sho...

therefore 48 patients only were pleomorphic.  in fact, the survivors could easily be the not so bad actors and we may be hurting patients. in their last days of life. I think we have to learn to say no without data, particularly when for years chemotherapy has been so marginal in soft ti...